"uniQure N.V. Raises $345 Million in Public Offering for Gene Therapy Advancements"

"Rutgers & Posch represented uniQure N.V. in a public offering of 6,736,841 ordinary shares at $47.50 each, along with pre-funded warrants for 526,316 shares, raising approximately $345 million. uniQure is developing gene therapies for serious conditions such as Huntington’s disease and ALS. The firm collaborated with Morgan Lewis for this offering."

Rutgers & Posch, in collaboration with US firm Morgan Lewis, represented NASDAQ listed uniQure N.V. in a significant public offering transaction. In this transaction, uniQure N.V. successfully offered 6,736,841 ordinary shares at a price of $47.50 per share, along with pre-funded warrants to purchase an additional 526,316 ordinary shares for certain investors. The gross proceeds from this offering amounted to approximately $345 million. uniQure is focused on developing proprietary gene therapies aimed at treating severe diseases, including Huntington’s disease, refractory temporal lobe epilepsy, ALS, and Fabry disease. The legal team from Rutgers & Posch included Bas Visée and Jamie Pellegrom, who advised uniQure on this transaction.

"uniQure N.V. Raises $345 Million in Public Offering for Gene Therapy Advancements"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads